BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9814953)

  • 1. Encouraging vaccine results from primate models of HIV type 1 infection.
    Schultz A
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S261-3. PubMed ID: 9814953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of primate models for AIDS.
    Haigwood NL
    AIDS Rev; 2004; 6(4):187-98. PubMed ID: 15700617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress and obstacles in the development of an AIDS vaccine.
    Letvin NL
    Nat Rev Immunol; 2006 Dec; 6(12):930-9. PubMed ID: 17124514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AIDS vaccine development in primate models.
    Almond NM; Heeney JL
    AIDS; 1998; 12 Suppl A():S133-40. PubMed ID: 9632994
    [No Abstract]   [Full Text] [Related]  

  • 5. AIDS vaccine development: the long and winding road.
    Garber DA; Feinberg MB
    AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on mucosal HIV vaccine vectors.
    Duerr A
    Curr Opin HIV AIDS; 2010 Sep; 5(5):397-403. PubMed ID: 20978380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
    Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
    AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV/AIDS vaccines: a need for new concepts?
    Girard MP; Bansal GP
    Int Rev Immunol; 2008; 27(6):447-71. PubMed ID: 19065351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of prophylactic AIDS vaccines: the current state of affairs.
    Hanke T
    Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candidate vaccines protect macaques against primate immunodeficiency viruses.
    Stott J; Hu SL; Almond N
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S265-70. PubMed ID: 9814954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV vaccine development at the turn of the 21st century.
    Girard MP; Plotkin SA
    Curr Opin HIV AIDS; 2012 Jan; 7(1):4-9. PubMed ID: 22156840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No vaccine against HIV yet--are we not perfectly equipped?
    Singh M
    Virol J; 2006 Aug; 3():60. PubMed ID: 16939652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AIDS vaccine models: challenging challenge viruses.
    Feinberg MB; Moore JP
    Nat Med; 2002 Mar; 8(3):207-10. PubMed ID: 11875482
    [No Abstract]   [Full Text] [Related]  

  • 14. [Vaccines against HIV].
    Holm-Hansen C
    Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3117-20. PubMed ID: 17160118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Murine models for HIV vaccination and challenge.
    Boberg A; Bråve A; Johansson S; Wahren B; Hinkula J; Rollman E
    Expert Rev Vaccines; 2008 Feb; 7(1):117-30. PubMed ID: 18251698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological considerations in the development of a human immunodeficiency virus vaccine.
    Nathanson N; Mathieson BJ
    J Infect Dis; 2000 Aug; 182(2):579-89. PubMed ID: 10915092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges.
    Ellenberger D; Otten RA; Li B; Aidoo M; Rodriguez IV; Sariol CA; Martinez M; Monsour M; Wyatt L; Hudgens MG; Kraiselburd E; Moss B; Robinson H; Folks T; Butera S
    Virology; 2006 Aug; 352(1):216-25. PubMed ID: 16725169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of nonhuman primates in the evaluation of candidate AIDS vaccines: an industry perspective.
    Staprans SI; Feinberg MB; Shiver JW; Casimiro DR
    Curr Opin HIV AIDS; 2010 Sep; 5(5):377-85. PubMed ID: 20978377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel strategies toward the development of an effective vaccine to prevent human immunodeficiency virus infection or acquired immunodeficiency virus.
    Ensoli B; Cafaro A
    AIDS Clin Rev; 2000-2001; ():23-61. PubMed ID: 10999215
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
    Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
    Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.